| Literature DB >> 34996384 |
Huan Chen1,2, Li-Yu Shan1,3, Tao Ma1, Yue Wang1, Zhe Feng1,3, Ding-Hui Dong1,3, Yi Lv1,3, Hao-Yang Zhu4,5.
Abstract
BACKGROUND: X-ray cholangiography is of great value in the imaging of biliary tract diseases; however, occupational radiation exposure is unavoidable. Moreover, clinicians must manually inject the contrast dye, which may result in a relatively high incidence of adverse reactions due to unstable injection pressure. Thus, there is a need to develop a novel remote-controlled cholangiography injection device.Entities:
Keywords: Cholangiography; Equipment design; Injection device; Occupational exposure; Remote control technology
Mesh:
Substances:
Year: 2022 PMID: 34996384 PMCID: PMC8742431 DOI: 10.1186/s12876-021-02087-8
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Fig. 1Flow diagram of the study
Fig. 2Remote-controlled cholangiography injection device. a Fabrication drawing. b Operation terminal. c Control terminal. d Extension tube. (1) Syringe slot, (2) syringe pushing hand—injection pump, (3) syringe fixing arm, (4) working status indicator, (5) direct-control panel, (6) pressure sensor, (7) on/off button, (8) power port, (9) pressure curve diagram, (10) parameter setting and display buttons, (11) control buttons, (12) T-adapter port, (13) syringe port, (14) pressure port
Fig. 3Clinical application of the remote-controlled cholangiography injection device. a Preparation of the device and assembly of the operation terminal, syringe and extension tube. b Cholangiography using the remote-controlled device
Demographic data of the experimental and control groups
| Experimental group | Control group | ||
|---|---|---|---|
| Age (mean ± SD/years) | 58.14 ± 14.25 | 56.55 ± 14.21 | 0.211 |
| Sex (male/female) | 127/123 | 120/134 | 0.425 |
| Classification of diseases | |||
| Biliary Calculi (male/female) | 81/95 | 90/115 | 0.678 |
| Hepato-Bilio-Pancreatic Cancer (male/female) | 18/13 | 15/9 | 0.739 |
| Liver transplantation (male/female) | 19/4 | 11/3 | > 0.999 |
| Others* (male/female) | 11/10 | 5/6 | 0.710 |
*Others include patients who underwent a second operation, choledochojejunostomy, etc.
Fig. 4Results of remote-controlled cholangiography. a Normal biliary system. The common bile duct, intrahepatic bile duct and part of the intestinal mucosa are exhibited. b Right hemihepatectomy. The common bile duct and left hepatic duct are well visualized. c Hilar cholangiocarcinoma. The left and right hepatic ducts and their branches can be fully visualized through PTCD. The common hepatic duct, common bile duct and duodenum are not visualized. d Multiple biliary calculus. Multiple filling defects of the biliary system are displayed. Dilation and filling defects of the right hepatic duct can be seen. e Magnetic compressing biliary-intestinal anastomosis. The bile duct was connected to the intestine by a pair of magnets. The biliary system and intestinal mucosa can be clearly seen. f Postorthotopic liver transplantation. The biliary system is visualized well, and the anastomosis of the common bile duct is unobstructed
Adverse reactions of the experimental and control groups
| Diseases | Groups | Numbers | ||
|---|---|---|---|---|
| With adverse reactions | Without adverse reactions | |||
| Biliary Calculi | Experimental group | 8 | 168 | 0.008 |
| Control group | 25 | 180 | ||
| Hepato-Bilio-Pancreatic Cancer | Experimental group | 1 | 30 | 0.086 |
| Control group | 4 | 20 | ||
| Liver transplantation | Experimental group | 1 | 22 | > 0.999 |
| Control group | 1 | 13 | ||
| Other | Experimental group | 0 | 21 | 0.111 |
| Control group | 2 | 9 | ||
| Total | Experimental group | 10 | 240 | 0.001 |
| Control group | 31 | 223 | ||
Relationship between adverse reactions and injection parameters
| Groups | Numbers | ||
|---|---|---|---|
| With adverse reactions | Without adverse reactions | ||
| Injection pressure (kPa) | |||
| 0–3 | 2 | 132 | < 0.001 |
| 3.1–7 | 1 | 70 | |
| 7.1–10 | 1 | 10 | |
| > 10 | 6 | 27 | |
| Injection speed (ml/s) | |||
| 0.1–0.3 | 5 | 42 | 0.035 |
| 0.4–0.7 | 3 | 134 | |
| 0.8–1 | 2 | 64 | |
| Injection dose (ml) | |||
| < 20 | 2 | 57 | 0.618 |
| 20–30 | 5 | 84 | |
| > 30 | 3 | 99 | |